FDA accepts NDA to review Affymax, Takeda chronic kidney disease drug
The US Food and Drug Administration (FDA) has accepted for reviewing Affymax and Takeda Global Research & Development Center's new drug application (NDA) for peginesatide (Hematide) as a treatment for anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.
Peginesatide, a synthetic, PEGylated peptidic compound, is a erythropoiesis stimulating agent (ESA) that binds and activates the erythropoietin receptor.
The NDA submission is based on data from two Phase 3 studies (Emerald 1 and 2) which evaluated the efficacy and safety of peginesatide.
The study compared once-monthly peginesatide with epoetin in maintaining Hb levels in CKD patients on dialysis with anemia.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250